

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 1

Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30 × 1.4 g [1.362 mL] Suppositories)	FIN	F 008 455

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Hydrocortisone (Micronized), USP	2.700	g				
Polysorbate 80, NF	1.5	mL				
Medisca NovaFilm TM Gel Base	15.0	mL				
Medisca SPG Supposi-Base TM	20.47	g				





TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 2

	Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30 × 1.4 g [1.362 mL] Suppositories)	FIN	F 008 455
--	--	-----	-----------

CIAL PREPARATORY CONSI	DERATIONS	
Ingredient-Specific Information		
Light Sensitive (protect from li	ght whenever possible):	Hydrocortisone, NovaFilm™ Gel Base
Oxygen Sensitive (protect from	oxygen whenever possible):	Polysorbate 80
Hygroscopic (protect from moi	sture whenever possible):	Polysorbate 80
Suggested Preparatory Guidelines		(()
Non-Sterile Preparat	ion	CK
<u>Processing Error /</u> <u>Testing Considerations</u> :		considerations during preparation, it is suggested to of the required quantities of ingredients.
Special Instruction:	may be classified as hazardous, p Antineoplastic and Other Hazard General Chapter <800> Hazard informational and not compendia and enforcement bodies. For info implementation context for USP	more Active Pharmaceutical Ingredients (APIs) that lease refer & verify the current NIOSH list of ous Drugs in Healthcare Settings. At this time, lous Drugs – Handling in Healthcare Settings is lly applicable unless otherwise specified by regulators rmation on the scope, intended applicability, and General Chapter <800>, see:
	environmental conditions, follow	ithin the appropriate facilities under adequate ing the necessary guidelines and procedures as stated hen handling hazardous drugs. Only trained and this formula.
	limited to, lab coat, protective sle	equipment (hazardous if applicable), such as but not eves, gloves both inner and outer if applicable, eard cover, eyewear, appropriate face mask, respirator cable must be worn at all times.
		procedures for hazardous drug handling including but port, storage, preparation, dispensing, administration,
		ity, please refer to all relevant guidance documents ode of Federal Regulations (CFR), Guidance for Policy Guides (CPGs).
		f very small quantities of ingredients. All calculations be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 3

	Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30 × 1.4 g [1.362 mL] Suppositories)	FIN	F 008 455
--	--	-----	-----------

SUGGESTED PREPARATION (for 30 x 1.4 g [1.362 mL])

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Hydrocortisone (Micronized), USP §	2.700	g			
Polysorbate 80, NF §	1.5	mL			
Medisca NovaFilm™ Gel Base §	15.0	mL			
Medisca SPG Supposi-Base™	20.47	g			

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction
1.	Preparatory step:
	A. Prepare a hot water bath.
	Specifications: Temperature: 40 to 45°C.
2.	Powder-liquid preparation:
	A. Combine and mix the following ingredients together to form a homogeneous liquid-like dispersion:
	-NovaFilm™ Gel Base -Polysorbate 80
	B Levigate the Hydrocortisone (Micronized) with the homogeneous liquid-like dispersion (Step 2A).
	End result: Homogeneous paste-like dispersion.
3.	Medium preparation:
	A. Using the hot water bath, melt the SPG Supposi-Base TM .
	Specifications: Maintain temperature between 40°C and 45°C.
	End result: Homogeneous liquid-like solution.
	IMPORTANT: Do not allow the temperature to exceed 45°C.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 4

	Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30×1.4 g [1.362 mL] Suppositories)	FIN	F 008 455

4. **Medium integration:**

A. Using the hot water bath, incrementally add the homogeneous paste-like dispersion (Step 2B) into the melted SPG Supposi-BaseTM (Step 3A).

Specifications: Continuously mix, using high-shear mixing techniques.

Maintain temperature between 40°C and 45°C.

End result: Homogeneous liquid-like dispersion.

5. Mold filling:

- A. Remove the homogeneous liquid-like dispersion (Step 4A) from the heat. With continuous stirring, allow to cool slightly, until the mixture is thicker (with a lotion-like consistency).
- B. Fill the 30 mold cavities with the mixture. If the mixture starts to solidify, reheat to 40 45°C, and repeat the filling procedure.

Note: Continuously mix during the transfer process in order to maintain homogeneity.

- C. Once the molds have been filled, allow the suppositories to cool to room temperature.
- D. If necessary, trim the tops of the suppositories with a sharp blade or a hot spatula.

6. Validation technique:

- A. Weigh 6 suppositories separately.
- B. The final weight of each suppository from Step 6A (not including the weight of the suppository shell) shall not be less than 90% and not more than 110% of the theoretically calculated weight 1.35 g in accordance to USP guidelines.

7. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 5

	Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30 × 1.4 g [1.362 mL] Suppositories)	FIN	F 008 455
--	--	-----	-----------

SUGGESTED PRESENTATION

	CECTEDTIN		MIMION			
	Estima Beyond-Use D		6 months, refrigerated, as per USP*.	Packaş Requirem		Individually wrapped in a foil and placed in a tightly closed, light-resistant suppository box or widemouth container.
		1	Use as directed. Do not exceed p dose.	prescribed	6	Keep in a dry place.
		2	Keep out of reach of children.		7	Equilibrate to room temperature before use.
	Auxiliary Labels	3	Consult your health care practitio other prescription or over-th medications are currently being u prescribed for future use.	ne-counter	8	Keep refrigerated (2°C – 8°C). Do not freeze.
		4	Do not take with alcohol, sl- tranquilizers or other CNS depres		9	May impair mental and/or physical ability. Use care when operating a car or machinery.
		5	Protect from light.		10	For rectal use only.
Pharmacist Instructions Add any auxiliary labels specific to the active ingredient to the dispensing container as deemed necess					ent to the dispensing container as deemed necessary.	
	Patient Instructions If allergic reactions occur, consult your pharmacist.					

^{*} The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/18/2020; Page 6

	Hydrocortisone 90 mg Mucoadhesive Rectal Suppositories (Solid Suspension, 30 × 1.4 g [1.362 mL] Suppositories)	FIN	F 008 455
--	--	-----	-----------

REFERENCES

1.	Suppositories and Insert. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.</i> American Pharmacists Association; 2016: 231.
2.	Hydrocortisone. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1535.
3.	Hydrocortisone (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4824.
4.	Hydrocortisone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 5 th Edition. American Pharmaceutical Association; 2012: 241.
5.	Hydrocortisone (Monograph). <i>United States Pharmacopeia XLII / National Formulary 37</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 2180.
6.	USP <795>. <i>United States Pharmacopeia XLII / National Formulary 37</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 6951.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.